Health-related quality of life among patients with moderate-to-severe plaque psoriasis in Taiwan-Reference-Cited by-同舟云学术

Health-related quality of life among patients with moderate-to-severe plaque psoriasis in Taiwan

Published:2018-12 Issue:4 Volume:36 Page:190-195
ISSN:1027-8117
Container-title:Dermatologica Sinica
language:en
Short-container-title:Dermatologica Sinica

Author:

Tsai Tsen-Fang,Ho Ji-Chen,Chen Yi-Ju,Hsiao Pa-Fan^ORCID,Lee Woan-Ruoh,Chi Ching-Chi^ORCID,Lan Cheng-Che,Hui Rosaline Chung-Yee,Lin Yang-Chih,Yang Kuo-Chia,Wong Tak-Wah^ORCID,Sheu Hamm-Ming,Hsu Hsiu-Cheng,Chu Gong-Yau,Huang Yu-Huei

Funder

AbbVie

Celgene Ltd.

Janssen

Eli Lilly

Norvatis

Boerhinger-Ingelheim

Galderma

Pfizer

Abbvie

Janssen Taiwan

Leo pharmacy

Pfizer Inc

Novartis

Boerhinber-Ingelheim

Janssen Taiwan Medical Affairs Writing

Janssen Taiwan, Johnson & Johnson Ltd

Janssen Taiwan Medical Affairs

Publisher

Medknow

Subject

Dermatology

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Predictors for the effectiveness of 75 mg risankizumab in treating psoriasis—A real‐word evidence from a 52‐week retrospective study;Experimental Dermatology;2023-10-21

2. Thymic stromal lymphopoietin: evaluating its role as a new marker related to presence of psoriasis vulgaris and its severity;Egyptian Journal of Dermatology and Venereology;2023-08-25

3. Risk Factors of Ixekizumab-Induced Injection Site Reactions in Patients with Psoriatic Diseases: Report from a Single Medical Center;Biomedicines;2023-06-15

4. 2022 Taiwanese Dermatological Association (TDA), Taiwanese Association for Psoriasis and Skin Immunology (TAPSI), and Taiwan Society of cardiology (TSOC) joint consensus recommendations for the management of psoriatic disease with attention to cardiovascular comorbidities;Journal of the Formosan Medical Association;2022-11

5. Topical Tirbanibulin, a Dual Src Kinase and Tubulin Polymerization Inhibitor, for the Treatment of Plaque-Type Psoriasis: Phase I Results;Pharmaceutics;2022-10-11